Clinical Research Studies

This is a prospective clinical study to evaluate the safety of an investigational new drug, CORT125134, in patients with endogenous Cushing’s syndrome for whom the Investigator has determined that medical treatment of endogenous hypercortisolemia is indicated. CORT125134 blocks glucocorticoid receptors in the body. The study will assess the effect of treatment on the signs and symptoms of hypercortisolemia. This study will also look for evidence of reduction in cortisol activity following treatment with CORT125134 in patients with endogenous Cushing’s syndrome, based on improvement in blood glucose control and/or blood pressure. We are looking to enroll patients with a diagnosis of endogenous Cushing’s syndrome.